

## Keytruda® (pembrolizumab) – Accelerated approval to full approval

- On December 16, 2022, the <u>FDA approved</u> Merck's <u>Keytruda (pembrolizumab)</u>, for an alternate dosing regimen of 400 mg every six weeks for all approved adult solid tumor indications.
  - The alternate dosing regimen was previously approved under accelerated approval in 2020. This converts the accelerated approval to full approval.
  - Two indications, adult classical Hodgkin lymphoma and adult primary mediastinal large B cell lymphoma, for the alternate dosing regimen continue to be approved under accelerated approval.
- The approval of Keytruda for the full approval alternate dosing regimen was based on an analysis
  of overall response rate, duration of response, and safety from Cohort B of the KEYNOTE-555
  trial, a phase 1 randomized trial of Keytruda to evaluate bioavailability of the dosing regimen.
  - There are no clinically significant exposure-response relationships for efficacy or safety at pembrolizumab dosages of 200 mg or 2 mg/kg every 3 weeks and 400 mg every 6 weeks in patients with solid tumors based on observed data in adult patients with melanoma.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.